Metropolis Healthcare Ltd. · NSE:METROPOLIS
Metropolis Healthcare — Q4 FY2025 Earnings Presentation
28 slides from Metropolis Healthcare's earnings presentation, May 13, 2025
Slide 1: Cover letter to stock exchanges
Ref: MHL/Sec&Legal/2025-26/12 May 13, 2025 To, BSE Limited National Stock Exchange of India Ltd. Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclos
Slide 2: Metropolis Healthcare Limited Q4FY25 Investor Presentation
METROPOLIS HEALTHCARE LIMITED Q4FY25 INVESTOR PRESENTATION
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Metropolis Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Content
Performance Highlights 1 Financial performance indicators Segment, volume and other Operational KPIs 2 performance indicators Content Performance and Profit & Loss 3 Income Statement Company Updates Q4 & FY25 Metropolis 3.0 Metropolis 3.0 strategy Strategy 4 including network, digital, science and q
Slide 5: Metropolis – Diagnostics that's trusted by doctors and patients alike
Metropolis – Diagnostics that’s trusted by doctors and patients alike OUR VISION To be a respected healthcare brand 43+ years of trusted by clinicians, patients and 11% CAGR stakeholders. credible revenue experience Positively impact the lives of patients in growth in last their most anxious times a
Slide 6: FY25 Key Performance Indicators
FY25 Key Performance Indicators • Consistently delivering Volume & Double Digit Revenue growth • Reported EBITDA & PAT were impacted due to one off expenses of ~Rs. 21 crs off which Revenue Adj EBITDA* PAT* • Majority consists of acquisition related expenses related to 3 acquisitions done in Q4FY25
Slide 7: Q4FY25 Key Performance Indicators
Q4FY25 Key Performance Indicators • Adj. EBITDA was affected during the quarter: • NIL margin from Core Diagnostics • Accelerated lab & center expansion in last 2 quarters Revenue • Lower than usual revenue in Adj EBITDA* PAT* February in our focus markets resulting into de-operating INR 345 Cr INR
Slide 8: FY25 Key Performance Indicators
FY25 Key Performance Indicators • Consistently achieving growth in patient and test volumes, even Patient Volume B2C Revenue B2B Revenue while strategically reducing exposure to low-margin 12.7 Mn INR 735 Cr INR 477 Cr institutional business +6% YoY +17% YoY +12% YoY • Strong B2C growth with focus o
Slide 9: Q4FY25 Key Performance Indicators
Q4FY25 Key Performance Indicators • Consistently delivering Patient & Patient Volume B2C Revenue B2B Revenue Test Volumes growth • Our Truhealth revenues grew by 3.16 Mn INR 193 Cr INR 120 Cr 20% on a Y-o-Y basis. Truhealth +6% YoY now contributes 19% of the overall +14% YoY +10% YoY revenues for Q4
Slide 10: Revenue growth on the back of increase in contribution from Truhealth & Specialty Segments
Revenue growth on the back of increase in contribution from Truhealth & Specialty Segments Patient Volume (in Mn) Test Volume (in Mn) Q4FY25 Segment Contribution Q4FY25 Segment Revenue Growth 9.7% Routine 6% 6% 7% Routine 17% 18% 6% 8% 6% Semi-Special Semi-Special 6% 12.00 12.67 24.67 26.43 Specialt
Slide 11: Strong B2C revenue growth @ 17% YoY in FY25
Strong B2C revenue growth @ 17% YoY in FY25 • Patient volume grew by 8%, with a robust 9% increase in RPP (Revenue Per Patient), enabled by enhanced upselling and value delivery • B2C Specialty grew by 21% YoY, driven by enhanced doctor engagement, 55% targeted programs and introduction of (+240bps)
Slide 12: B2B revenue growing by 12% YoY in FY25
B2B revenue growing by 12% YoY in FY25 • Patient volume grew by 4%, with a notable 8% increase in RPP, driven by value-focused strategies and superior service delivery • Dedicated focus on enhancing B2B 36% service quality & partner engagement programs +19% • Partner portal has further strengthened
Slide 13: TruHealth Revenue grew @ 24% YoY for FY25
TruHealth Revenue grew @ 24% YoY for FY25 o Margin-Accretive Growth: Focused on high-yield health packages, driving average realizations above ₹2,500 and reinforcing a strategy centered on premium value delivery and profitability Growth o Enhanced Customer Service Initiatives: • Integrated Home-base
Slide 14: Speciality Revenue grew @ 13% YoY for FY25
Speciality Revenue grew @ 13% YoY for FY25 o Comprehensive Specialty Offering: Over 3,000 specialty tests and uniquely Specialty curated profiles across Gastroenterology, Nephrology, Neurology, Oncology, Growth Women & Child Health, Infectious Diseases, and Chronic Conditions. o Driving more consume
Slide 15: Network Expansion – Robust expansion with consolidation laying strong base
Network Expansion – Robust expansion with consolidation laying strong base Laboratory Network Service Network 199 210 4,536 Rationalization Period 4,150 3,675 870 175 +1,981 161 805 124 125 +85 2,731 2,555 3,134 704 754 119 Labs 2,336 598 498 Centres 575 3,135 2,914 2,594 2,105 Rural 1,873 1,806 1,5
Slide 16: Diversified Revenue contribution across Geographies
Diversified Revenue contribution across Geographies FY25 Revenue Contribution Revenue Growth (MHL Categorisation) Focus 8.0% 12.9% 18% By Cities Focus Seeding Seeding 6.0% 8.6% 19% Others 63% Others 18.6% Revenue growth (ex of institutional business) Revenue Contribution Revenue Growth Presence in ~
Slide 17: Q4 & FY25 Consolidated Profit & Loss Statement
Q4 & FY25 Consolidated Profit & Loss Statement Profit & Loss Statement (Rs. Crs.) Q4FY25 Q4FY24 Y-o-Y FY25 FY24* Y-o-Y Revenue from Operations 345 313 10% 1,331 1,189 12% Costs 261 233 1,006 904 One off expenses pertaining to Adj EBITDA 84 80 5% 325 285 14% • Majority consists of Adj EBITDA (%) 24.3
Slide 18: Balance Sheet Overview
Balance Sheet Overview Equity & Liabilities (Rs. Crs.) Mar-25 Mar-24 Assets (Rs. Crs.) Mar-25 Mar-24 Equity 1,334.6 1,091.0 Non-current assets 1,521.4 1,237.7 Equity Share capital 10.4 10.2 Property, Plant and Equipment 190.3 154.7 Other equity 1,320.6 1,077.6 ROU Assets 170.3 180.1 Non Controlling
Slide 19: Metropolis 3.0
Metropolis 3.0 METROP®OLIS
Slide 20: Key Pillars of Metropolis 3.0 Strategy – poised to grow further
Key Pillars of Metropolis 3.0 Strategy – poised to grow further 1 2 Strengthening the Core Expand to Adjacencies Expand market share in core and while Forging New Alliances newer geographies with a focus Expanding into adjacencies like on specialized and wellness complimenting radiology, allied test
Slide 21: Driving business growth through Digital Transformation
Driving business growth through Digital Transformation Metropolis is a unique Healthcare Company equipped with SalesForce CDP, Marketing Cloud, Service Cloud, Sales Cloud, Community Cloud Accurate Efficient Efficient 360-Degree Opportunity Case Relationship Reporting & Cross Enhanced Billing & Patie
Slide 22: Scientifically driven with strong focus on quality, research and academics
Scientifically driven with strong focus on quality, research and academics Scientific Expansion in Test Menu • New test launched across Oncology, Nephrology, Gynecology 60+ New Tests added in FY25 and Infectious and Chronic disease segment • Focus on NGS/molecular genomics segment growing driven and
Slide 23: Metropolis ESG Goals
Metropolis ESG’ Goals • Carbon Neutrality by 2043 Emission Goals for a Greener • 45% reduction in emissions intensity Well identified ESG Focus Areas and Tomorrow by 2030 e assessments created as per the materiality matrix based on the GRI, SASB and SDG Frameworks. Our first Business Responsibility
Slide 24: Key ESG Plans
Key ESG Plans Emissions & Water & Waste Employee Risk Patient Privacy Energy Management Recruitment, Management and Electronic Development and Health Records Retention • Achieve 5% reduction • Career 2.0 Campaign to • Annual assessments of • 100% training on • Achieve 10% reduction in water usage in
Slide 25: CSR at Metropolis – creating a positive impact
CSR at Metropolis – creating a positive impact Preventive DSEU* (Delhi Skills MedEngage Too Shy to Ask(TSTA) Entrepreneurial healthcare Project University) • Integrating all UG and • TSTA Rural focusing on • 1000 TB patients to receive PG programs including adolescent reproductive and nutritional su
Slide 26: 'Promoter led – Professionally driven' organisation
‘Promoter led – Professionally driven’ organisation Dr. Sushil Shah Ameera Shah Surendran Chemmenkotil Chairman Emeritus Promoter & Executive Chairperson Chief Executive Officer Dynamic Leadership Team for Next Level of Growth Dr. Nilesh Shah Sameer Patel Diya Suri Dr. Kirti Kazi President - Interna
Slide 27: Recent Awards and Accolades
Recent Awards and Accolades Ameera Shah – Most Powerful Woman in Business by Fortune India for the year Apr’25 2025 Mar’25 Ameera Shah – Most Influential Women in India 2025 by Business World Metropolis Healthcare – WOW Workplace Award for the year 2025 in the Feb’25 Pharmaceutical and Healthcare ca
Slide 28: For further information, please contact
For further information, please contact: Company : Investor Relations Advisors : http://www.sgapl.net/images/sgapl_logo.jpg Metropolis Healthcare Ltd. Strategic Growth Advisors Pvt. Ltd. CIN – L73100MH2000PLC192798 CIN - U74140MH2010PTC204285 Mr. Kamlesh Kulkarni Mr. Shogun Jain / Mr. Sagar Shroff E
Metropolis Healthcare — Q4 FY2025 Earnings Presentation on 6ix